Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1393-1399

  Matsuoka, Hiromichi ^a   Arao, Tokuzo ^a   Makimura, Chihiro ^a   Takeda, Masayuki ^a   Kiyota, Hidemi ^a   Tsurutani, Junji ^a   Fujita, Yoshihiko ^a   Matsumoto, Kazuko ^a   Kimura, Hideharu ^a   Otsuka, Masatomo ^a   Koyama, Atsuko ^a   Imamura, Chiyo K ^b   Tanigawara, Yusuke ^b   Yamanaka, Takeharu ^c   Tanaka, Kyoko ^d   Nishio, Kazuto ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d Osaka Prefecture University   (Japan)

Author keywords

Arrestin; Catechol O methyltransferase; Microarray; Morphine; Opioid receptor 1

Indexed keywords

ADENINE; BETA ARRESTIN 1; BETA ARRESTIN 2; BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; DELTA OPIATE RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 4; G PROTEIN COUPLED RECEPTOR KINASE 5; G PROTEIN COUPLED RECEPTOR KINASE 6; GUANINE; MESSENGER RNA; MORPHINE; MU OPIATE RECEPTOR; RGS PROTEIN; RGS2 PROTEIN; RGS9 PROTEIN; RHODOPSIN KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARRB1 GENE; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; COMT GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOCYTE; LIQUID CHROMATOGRAPHY; LUNG CANCER; MALE; MICROARRAY ANALYSIS; OPRM1 GENE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ARRESTINS; BIOLOGICAL MARKERS; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84863248608     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1660     Document Type: Article

References (26)

1. Lötsch J, Geisslinger G and Tegeder I: Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 124: 168-184, 2009.
2. Marie N, Aguila B and Allouche S: Tracking the opioid receptors on the way of desensitization. Cell Signal 18: 1815-1833, 2006. (Pubitemid 44485992)
3. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP and Kieffer BL: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383: 819-823, 1996.
4. Neubig RR and Siderovski DP: Regulators of G-protein signalling as new central nervous system drug targets. Nat Rev Drug Discov 1: 187-197, 2002. (Pubitemid 37361422)
5. Garzón J, Rodríguez-Díaz M, López-Fando A and Sánchez-Blázquez P: RGS9 proteins facilitate acute tolerance to mu-opioid effects. Eur J Neurosci 13: 801-811, 2001.
6. Potenza MN, Gold SJ, Roby-Shemkowitz A, Lerner MR and Nestler EJ: Effects of regulators of G protein-signaling proteins on the functional response of the mu-opioid receptor in a melanophore-based assay. J Pharmacol Exp Ther 291: 482-491, 1999. (Pubitemid 29503515)
7. Freedman NJ and Lefkowitz RJ: Desensitization of G protein-coupled receptors. Recent Prog Horm Res 51: 319-351, 1996. (Pubitemid 126476619)
8. Ueda H, Inoue M and Matsumoto T: Protein kinase C-mediated inhibition of mu-opioid receptor internalization and its involvement in the development of acute tolerance to peripheral mu-agonist analgesia. J Neurosci 21: 2967-2973, 2001. (Pubitemid 32323477)
9. Whistler JL, Chuang HH, Chu P, Jan LY and von Zastrow M: Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23: 737-746, 1999. (Pubitemid 29411563)
10. Tremblay J and Hamet P: Genetics of pain, opioids, and opioid responsiveness. Metabolism 59 (Suppl 1): S5-S8, 2010.
11. Hosák L: Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry 22: 276-281, 2007.
12. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N and Nishio K: mTOR signal and hypoxia-inducible factor-1α regulate CD133 expression in cancer cells. Cancer Res 69: 7160-7164, 2009.
13. Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K and Nishio K: FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res 70: 2053-2063, 2010.
14. Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, Shimada Y, Hamaguchi T, Kato K, Hamano T, Koizumi F, Tamura T, Saito D, Shimoda T, Saka M, Fukagawa T, Katai H, Sano T, Sasako M and Nishio K: Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci 99: 2193-2199, 2008.
15. Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R and Nakagawa K: Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 9: 2825-2833, 2010.
16. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ and Caron MG: Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27: 107-144, 2004. (Pubitemid 39050399)
17. Ma L and Pei G: β-arrestin signaling and regulation of transcription. J Cell Sci 120: 213-218, 2007.
18. Eisinger DA, Ammer H and Schulz R: Chronic morphine treatment inhibits opioid receptor desensitization and internalization. J Neurosci 22: 10192-10200, 2002. (Pubitemid 35416858)
19. Domschke K and Deckert J: Genetics. Curr Top Behav Neurosci 2: 63-75, 2010.
20. Xu K, Ernst M and Goldman D: Imaging genomics applied to anxiety, stress response, and resiliency. Neuroinformatics 4: 51-64, 2006. (Pubitemid 43780278)
21. Calati R, Porcelli S, Giegling I, et al: Catechol-O-methyl-transferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. J Psychiatr Res 45: 309-321, 2011.
22. Zai CC, Tiwari AK, Müller DJ, et al: The catechol-O-methyl- transferase gene in tardive dyskinesia. World J Biol Psychiatry 11: 803-812, 2010.
23. Zubieta JK, Heitzeg MM, Smith YR, et al: COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299: 1240-1243, 2003. (Pubitemid 36237467)
24. Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S and Klepstad P: Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 4: 64, 2008.
25. Reyes-Gibby CC, Shete S, Rakvåg T, Bhat SV, Skorpen F, Bruera E, Kaasa S and Klepstad P: Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130: 25-30, 2007. (Pubitemid 46850782)
26. Rakvåg TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE and Skorpen F: The Val158Met polymorphism of the human catechol-O- methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116: 73-78, 2005.